Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 우주현 | * |
dc.date.accessioned | 2021-02-04T16:31:00Z | - |
dc.date.available | 2021-02-04T16:31:00Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 0167-6806 | * |
dc.identifier.other | OAK-28662 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/256845 | - |
dc.description.abstract | Purpose: The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials. The objective of this study was to evaluate the survival of patients in a monoethnic group diagnosed with T1b lymph node-negative breast cancer depending on HER2 status. Methods: We analyzed 3110 patients with T1bN0M0 breast cancer whose data were deposited into the Korean Breast Cancer Society Registry database between 2000 and 2009. Overall survival (OS) and breast cancer-specific survival (BCSS) were compared according to HER2 status. Results: Among all patients, 494 (15.9%) had HER2-positive breast cancer. At a mean follow-up of 93 months, 108 deaths and 86 breast cancer-specific deaths were noted among all patients. There was no significant difference in OS between the HER2-negative and HER2-positive groups (p = 0.103). The same result was observed for BCSS. However, in the subgroup of estrogen receptor (ER)-positive women, HER2-negative patients had a better BCSS prognosis than HER2-positive patients (p = 0.025). Multivariate analysis also indicated a significant difference in BCSS in the ER-positive subgroup (HR 2.60; 95% CI 1.15–5.87; p = 0.021). Conclusion: This study analyzed a large nationwide and monoethnic cohort and found a significant difference only in BCSS in the ER-positive subgroup according to HER2 status. Anti-HER2 therapy may be considered in HER2-positive and ER-positive patients with small, node-negative breast cancer. © 2021, Springer Science+Business Media, LLC, part of Springer Nature. | * |
dc.language | English | * |
dc.publisher | Springer | * |
dc.subject | Breast cancer | * |
dc.subject | ERBB-2 | * |
dc.subject | Human epidermal growth factor receptor 2 | * |
dc.subject | Intrinsic factor | * |
dc.subject | Trastuzumab | * |
dc.title | Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 186 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 125 | * |
dc.relation.lastpage | 134 | * |
dc.relation.journaltitle | Breast Cancer Research and Treatment | * |
dc.identifier.doi | 10.1007/s10549-020-06017-2 | * |
dc.identifier.scopusid | 2-s2.0-85098591778 | * |
dc.author.google | Kang Y.-J. | * |
dc.author.google | Oh S.J. | * |
dc.author.google | Choi H. | * |
dc.author.google | Cho S. | * |
dc.author.google | Shin C.-H. | * |
dc.author.google | Kim C. | * |
dc.author.google | Woo J. | * |
dc.author.google | Lee J.S. | * |
dc.author.google | Park H.K. | * |
dc.author.google | Lee H.-B. | * |
dc.author.google | Noh W.C. | * |
dc.author.google | Kim Y.-S. | * |
dc.contributor.scopusid | 우주현(56211277800) | * |
dc.date.modifydate | 20240318132538 | * |